Centro Médico del Sueño, Division of Neurosciences, Pontificia Universidad Catolica de Chile, Chile.
Centro Médico del Sueño, Division of Neurosciences, Pontificia Universidad Catolica de Chile, Chile.
Sleep Med. 2014 Feb;15(2):163-7. doi: 10.1016/j.sleep.2013.10.010. Epub 2013 Dec 13.
We aimed to describe a group of adults diagnosed with sleep-related eating disorder (SRED) at the Sleep Medicine Center of the Pontificia Universidad Catolica de Chile.
We performed a descriptive study of 34 consecutive patients who met the criteria of the International Classification of Sleep Disorders for SRED evaluated during a 3-year period who did not have an eating disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. All patients had a structured clinical interview performed by a sleep specialist and completed the Beck Depression Inventory (BDI). Polysomnography (PSG) was performed when clinically indicated for ruling out other sleep-related disorders (18 patients; 52.9%). Patients' demographic and clinical data, comorbidities, and treatment response also were analyzed.
Most patients were women (n=23; 67.6%). The average age at the time of diagnosis was 39±13.8 (17-67 years) and the latency since symptom onset was 8.3±8.8 years. Most patients had several episodes per night (average, 2.6±1.6; 1-8) and all except one patient had partial or total amnesia of these events (n=33; 97%). Comorbidities were frequent and included insomnia (n=20; 58.8%), restless legs syndrome (RLS) (n=16; 47%), sleep-disordered breathing (SDB) (n=9; 26%), psychiatric disorders (n=13; 38.2%), and overweight or obesity (n=14; 41.1%). Most patients were hypnotic users (n=21; 61.7%) and reported weight-centered anxiety (n=23; 67.6%). Twenty patients (58.8%) were treated with topiramate, 17 of whom had adequate symptomatic responses.
Our SRED patients showed female preponderance, amnesia during the episodes, association with other sleep disorders, use of hypnotics, weight-centered anxiety, and positive response to topiramate. The presence of anxiety focused on weight in most patients may be an important element in the emergence of this behavior during sleep.
我们旨在描述在智利天主教大学睡眠医学中心诊断为睡眠相关进食障碍（SRED）的一组成年人。
我们对在三年内符合国际睡眠障碍分类 SRED 标准且根据第四版精神障碍诊断与统计手册标准无进食障碍的 34 例连续患者进行了描述性研究。所有患者均由睡眠专家进行了结构化临床访谈，并完成了贝克抑郁量表（BDI）。当临床需要排除其他睡眠相关障碍时（18 例；52.9%），进行了多导睡眠图（PSG）。还分析了患者的人口统计学和临床数据、合并症和治疗反应。
大多数患者为女性（n=23；67.6%）。诊断时的平均年龄为 39±13.8（17-67 岁），症状发作后的潜伏期为 8.3±8.8 年。大多数患者每晚发作数次（平均 2.6±1.6；1-8 次），除 1 例患者外，所有患者均对这些事件存在部分或完全遗忘（n=33；97%）。合并症很常见，包括失眠（n=20；58.8%）、不宁腿综合征（RLS）（n=16；47%）、睡眠呼吸障碍（SDB）（n=9；26%）、精神障碍（n=13；38.2%）和超重或肥胖（n=14；41.1%）。大多数患者为催眠药使用者（n=21；61.7%），并报告有体重相关的焦虑（n=23；67.6%）。20 名患者（58.8%）接受了托吡酯治疗，其中 17 名患者的症状得到了充分缓解。
我们的 SRED 患者表现出女性优势、发作期间的遗忘、与其他睡眠障碍相关、使用催眠药、体重相关的焦虑以及对托吡酯的阳性反应。大多数患者存在以体重为中心的焦虑，这可能是这种行为在睡眠中出现的一个重要因素。
